{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:49:54Z","timestamp":1792460994890,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["INNPACTO program [IPT-2012-0062-010000]."],"award-info":[{"award-number":["INNPACTO program [IPT-2012-0062-010000]."]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40744-021-00345-5","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:02:36Z","timestamp":1626627756000},"page":"1323-1339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial"],"prefix":"10.1007","volume":"8","author":[{"given":"Catalina","family":"G\u00f3mez-Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inigo","family":"Gorostiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"\u00dacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luz","family":"Garc\u00eda-Vivar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Eugenia","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ramon","family":"De Dios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruibal-Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Vasques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Belzunegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziortza","family":"Trancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Ruiz del Agua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Jorquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nagore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,18]]},"reference":[{"key":"345_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"345_CR2","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","volume":"52","author":"LC Coates","year":"2013","unstructured":"Coates LC, Tillett W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford). 2013;52:1754\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"345_CR3","first-page":"898","volume":"32","author":"YM Chiu","year":"2014","unstructured":"Chiu YM, Lai MS, Lin HY, Lang HC, Lee LJ, Wang JD. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol. 2014;32:898\u2013903.","journal-title":"Clin Exp Rheumatol"},{"key":"345_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.reuma.2009.10.006","volume":"6","author":"J Tornero Molina","year":"2010","unstructured":"Tornero Molina J, Sanmarti Sala R, Rodriguez Valverde V, et al. Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin. 2010;6:23\u201336.","journal-title":"Reumatol Clin"},{"key":"345_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165\u201378.","journal-title":"Ann Rheum Dis"},{"key":"345_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/ard.2009.108787","volume":"69","author":"AW van Kuijk","year":"2010","unstructured":"van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69:624\u20135.","journal-title":"Ann Rheum Dis"},{"key":"345_CR7","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1002\/art.34680","volume":"64","author":"CL Krieckaert","year":"2012","unstructured":"Krieckaert CL, Jamnitski A, Nurmohamed MT, Kostense PJ, Boers M, Wolbink G. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum. 2012;64:3850\u20135.","journal-title":"Arthritis Rheum"},{"key":"345_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460\u20138.","journal-title":"JAMA"},{"issue":"Suppl 4","key":"345_CR9","doi-asserted-by":"publisher","first-page":"iv39","DOI":"10.1093\/rheumatology\/ker245","volume":"50","author":"L Bojke","year":"2011","unstructured":"Bojke L, Epstein D, Craig D, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology (Oxford). 2011;50(Suppl 4):iv39\u201347.","journal-title":"Rheumatology (Oxford)"},{"key":"345_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00252.x","volume":"11","author":"G Kobelt","year":"2008","unstructured":"Kobelt G, Sobocki P, Mulero J, Gratacos J, Pocovi A, Collantes-Estevez E. The burden of ankylosing spondylitis in Spain. Value Health. 2008;11:408\u201315.","journal-title":"Value Health"},{"key":"345_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15suppl1-01","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u2013329.","journal-title":"Health Technol Assess"},{"key":"345_CR12","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.23374","volume":"58","author":"AJ Wailoo","year":"2008","unstructured":"Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008;58:939\u201346.","journal-title":"Arthritis Rheum"},{"key":"345_CR13","first-page":"101","volume":"9","author":"E Dreesen","year":"2017","unstructured":"Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clin Pharmacol. 2017;9:101\u201311.","journal-title":"Clin Pharmacol"},{"key":"345_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921\u20136.","journal-title":"Ann Rheum Dis"},{"key":"345_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","volume":"74","author":"MF Pouw","year":"2015","unstructured":"Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74:513\u20138.","journal-title":"Ann Rheum Dis"},{"key":"345_CR16","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/rheumatology\/keq060","volume":"49","author":"AA den Broeder","year":"2010","unstructured":"den Broeder AA, van der Maas A, van den Bemt BJ. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology (Oxford). 2010;49:1801\u20133.","journal-title":"Rheumatology (Oxford)"},{"key":"345_CR17","first-page":"174","volume":"33","author":"S Arends","year":"2015","unstructured":"Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33:174\u201380.","journal-title":"Clin Exp Rheumatol"},{"key":"345_CR18","doi-asserted-by":"publisher","first-page":"081","DOI":"10.1136\/annrheumdis-2019-215546","volume":"79","author":"H Marotte","year":"2020","unstructured":"Marotte H, Rinaudo-Gaujous M, Petiet C, Fautrel B, Paul S. Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study. Ann Rheum Dis. 2020;79:081.","journal-title":"Ann Rheum Dis"},{"key":"345_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","volume":"54","author":"I Gonzalez-Alvaro","year":"2015","unstructured":"Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54:1200\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"345_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1586\/erp.13.24","volume":"13","author":"I de la Torre","year":"2013","unstructured":"de la Torre I, Valor L, Nieto JC, et al. Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification. Expert Rev Pharmacoecon Outcomes Res. 2013;13:407\u201314.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"345_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/annrheumdis-2013-204101","volume":"74","author":"CL Krieckaert","year":"2015","unstructured":"Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis. 2015;74:361\u20138.","journal-title":"Ann Rheum Dis"},{"key":"345_CR22","first-page":"67","volume":"10","author":"J Laine","year":"2016","unstructured":"Laine J, Jokiranta TS, Eklund KK, Vakevainen M, Puolakka K. Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-alpha blockers. Biologics. 2016;10:67\u201373.","journal-title":"Biologics"},{"key":"345_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337\u201343.","journal-title":"Ann Med"},{"key":"345_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/1471-2474-14-299","volume":"14","author":"AA den Broeder","year":"2013","unstructured":"den Broeder AA, van Herwaarden N, van der Maas A, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord. 2013;14:299.","journal-title":"BMC Musculoskelet Disord"},{"key":"345_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","volume":"21","author":"JM Ramos-Go\u00f1i","year":"2018","unstructured":"Ramos-Go\u00f1i JM, Craig BM, Oppe M, et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. Value Health. 2018;21:596\u2013604.","journal-title":"Value Health"},{"key":"345_CR26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hec.3633","volume":"27","author":"L Vallejo-Torres","year":"2018","unstructured":"Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27:746\u201361.","journal-title":"Health Econ"},{"key":"345_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","volume":"77","author":"MJ I\u2019Ami","year":"2018","unstructured":"I\u2019Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77:484\u20137.","journal-title":"Ann Rheum Dis"},{"key":"345_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-016-1266-1","volume":"52","author":"L Martelli","year":"2017","unstructured":"Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L. Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. J Gastroenterol. 2017;52:19\u201325.","journal-title":"J Gastroenterol"},{"key":"345_CR29","first-page":"131","volume":"29","author":"L Lamot","year":"2011","unstructured":"Lamot L, Bukovac LT, Vidovic M, Frleta M, Harjacek M. The \u201chead-to-head\u201d comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29:131\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 3","key":"345_CR30","doi-asserted-by":"publisher","first-page":"A227","DOI":"10.1136\/annrheumdis-2013-eular.717","volume":"72","author":"DP Pascual-Salcedo","year":"2013","unstructured":"Pascual-Salcedo DP, Plasencia C, del Gonzalez Valle L. THU0189\u2005Therapeutic drug monitoring (TDM) in rheumatic day clinic enables to reduce pharmaceutical cost maintaining clinical efficacy. Ann Rheum Dis. 2013;72(Suppl 3):A227.","journal-title":"Ann Rheum Dis"},{"key":"345_CR31","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/MLR.0b013e3181a31971","volume":"47","author":"DA Marshall","year":"2009","unstructured":"Marshall DA, Hux M. Design and analysis issues for economic analysis alongside clinical trials. Med Care. 2009;47:S14-20.","journal-title":"Med Care"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00345-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-021-00345-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-021-00345-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T08:15:32Z","timestamp":1629620132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-021-00345-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,18]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["345"],"URL":"https:\/\/doi.org\/10.1007\/s40744-021-00345-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,18]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}